Literature DB >> 616607

Effects of neostigmine and pyridostigmine at the neuromuscular junction.

J D Gillies, J Allen.   

Abstract

The effect of subcutaneous administration of pyridostigmine or neostigmine for 7 to 15 days on neuromuscular transmission has been studied in the rat phrenic nerve-hemidiaphragm preparation. The quantal contents of end-plate potentials at different stimulus rates and the amplitude and frequency of miniature end-plate potentials were compared with those of untreated controls. The rate of release of acetylcholine quanta at high stimulus rates, and the frequency of miniature end-plate potentials, were reduced by pretreatment with both pyridostigmine and neostigmine. Presynaptic effects differed in that the number of quanta released by each nerve impulse at a stimulus rate of 1/sec was not altered by pyridostigmine, but was reduced to 52% of normal by neostigmine. The amplitude of miniature end-plate potentials was reduced to 81% by pretreatment with neostigmine and to 54% by pretreatment with pyridostigmine. The cause appears to be a reduction in the number of acetylcholine receptor sites as a result of disorganisation of the postsynaptic muscle membrane, which may contribute to the muscular weakness associated with the long term use of anticholinesterase agents.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 616607

Source DB:  PubMed          Journal:  Clin Exp Neurol        ISSN: 0196-6383


  2 in total

1.  Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; Hayley Ramjattan; Sandeep Jayawant; Stephanie A Robb; David Beeson
Journal:  Neurology       Date:  2015-09-22       Impact factor: 9.910

2.  β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.

Authors:  An E Vanhaesebrouck; Richard Webster; Susan Maxwell; Pedro M Rodriguez Cruz; Judith Cossins; James Wickens; Wei-Wei Liu; Hakan Cetin; Jonathan Cheung; Hayley Ramjattan; Jacqueline Palace; David Beeson
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.